p53转录非依赖活性介导细胞凋亡

p53主要通过两条途径诱导细胞凋亡：p53作为转录因子,促进细胞凋亡的靶基因的表达上调,如PUMA、NOXA、PIDD、p53AIP1、COP1等,并通过这些蛋白参与内源和外源凋亡途径;另一方面,胞浆中的p53能转位到线粒体,激活内源性的线粒体途径,促进凋亡。后者已成为研究p53促凋亡机制的热点。本文就p53对转录非依赖活性诱导细胞凋亡途径的研究进展作一概述。     

细胞凋亡中p53转录依赖与非依赖性调控

p53介导由胞内压力诱导的细胞凋亡等多种细胞应答.传统上认为, p53主要在细胞核内作为转录因子调控多种促凋亡靶基因的表达, 从而发挥其促凋亡功能.而最新的研究表明, p53也能直接在细胞质中发挥其促凋亡作用, 并且该过程不依赖于其核内的转录活性.此外, 在特定的刺激下, p53的转录依赖性(细胞核内)与转录非依赖性(细胞质内)促凋亡作用存在着偶联和协同机制, 从而有效的决定细胞在生存与死亡间进行选择.现对近年来关于细胞凋亡中p53转录依赖性和转录非依赖性调控及它们之间的偶联机制的研究进行综述.     

PUMA在结肠癌细胞中的表达及诱导细胞凋亡中的作用

目的:通过5-Fu诱导携带有野生型p53基因的HCT116和携带有突变性p53基因的HT-29两种结肠癌细胞系,比较两株细胞在各时间点凋亡水平和PUMA mRNA表达情况的差异,探讨PUMA对细胞凋亡的作用及诱导其表达的基本途径。方法:用逆转录聚合酶链反应(RT—PCR)检测不同结肠癌细胞株HT-29、HCT116在抗肿瘤药物5-Fu作用下不同时间点结肠癌细胞株内PUMA mRNA表达水平的差异,用吖啶橙/溴化乙啶(AO/EB)荧光染色检测各时间点细胞的凋亡水平,分析其与PUMAmRNA表达水平之间的关系。结果:携带有野生型P53基因的结肠癌细胞株HCT116在5-Fu作用下6h即可出现PUMA mRNA的表达,随着药物作用时间的延长其表达强度增加,并且与细胞凋亡水平呈正相关;含有突变型P53基因的结肠癌细胞株HT-29在5-Fu作用下无PUMA的表达。结论:通过5-Fu诱导细胞凋亡出现的PUMA表达需要野生型P53基因,突变型P53基因无法诱导PUMA的表达。PUMA与结肠癌细胞凋亡水平呈正相关,是一种促凋亡蛋白。     

异构体ΔASPP2可拮抗ASPP2对p53（细胞）凋亡功能的增强作用

p53 凋亡刺激蛋白2(apoptosis stimulating protein 2 of p53, ASPP2)能够与p53 蛋白结合特异性地增强其促细胞凋亡功能,进而发挥肿瘤抑制作用．我们发现的1个比ASPP2少300多个N端氨基酸的异构体ΔASPP2.目前,ΔASPP2对p53起何种作用尚不清楚．在本研究中,我们构建了rAd-ASPP2、rAd-ΔASPP2腺病毒,利用rAd-p53、rAd-ASPP2、rAd-ΔASPP2 感染p53缺失的细胞系H1299,在MMS的作用下研究ASPP2 和 ΔASPP2 对p53介导的细胞凋亡的影响．结果发现,p53自身过表达能明显促进肿瘤细胞的凋亡;ASPP2可显著增强p53介导的MMS引起的H1299细胞凋亡的作用;然而,ΔASPP2对p53介导的细胞凋亡没有明显影响但却显著抑制rAd-ASPP2 增强的rAd-p53的促细胞凋亡作用．p53-ASPP2 复合体可能改变p53 蛋白的构象,促进p53 和增强子Bax的结合活性．p53 转录调控基因的表达研究显示,ΔASPP2的存在可显著抑制ASPP2增强p53 介导的bax基因转录活性, 提示ΔASPP2可能与ASPP2结合后来抑制p53的凋亡基因转录活性．     

PUMA对人体肿瘤的促凋亡作用

p53上调凋亡调控因子(p53 up-regulated modulator of apoptosis,PUMA)是Bcl-2蛋白家族的促凋亡成员之一,具有强大的促凋亡作用。研究发现PUMA表达水平降低与肿瘤的发生密切相关,上调肿瘤细胞中PUMA的表达可以增强肿瘤细胞对放化疗的敏感性,说明PUMA是一个非常有前景的肿瘤基因治疗靶点。本文简要综述了PUMA对人体肿瘤促凋亡作用的研究进展。     

p53上调凋亡调制物的促凋亡作用

p53上调凋亡调制物(p53up-regulated modulator of apoptosis,PUMA)是Bcl-2家族中BH3-only(Bcl-2 homology 3-only)蛋白质家族成员,通过其BH3结构域与所有的Bcl-2抗凋亡蛋白质结合,引发线粒体功能障碍和胱天蛋白酶(caspase)级联反应,诱导细胞凋亡。PUMA被证实在多种病理性应激介导的细胞凋亡中发挥着至关重要的作用,因而成为近年研究的热点。     

促凋亡基因p53AIP1的研究进展

p53AIPl基因是近年发现的促凋亡基因,在p53依赖性的凋亡通路中起重要作用。p53AIPl介导线粒体凋亡途径,其表达依赖于p53蛋白的Ser^46的磷酸化。p53AIPl可直接促进凋亡,其促凋亡作用可能强于p53本身,并对p53抗性的肿瘤细胞也有作用。因此,对p53AIPl的深入研究可能会为对p53基因治疗有抗性的肿瘤患者带来新的希望。     

大鼠心肌细胞凋亡的保护作用

为探讨p53上调凋亡调制物(p53 up-regulated modulator of apoptosis, PUMA)在大鼠心肌细胞缺氧/复氧（hypoxia/reoxygenatio, H/R）损伤中的作用,本 研究将靶向PUMA的siRNA（si-PUMA）转染大鼠心肌细胞以建立PUMA沉默表达模型,观察其对心肌细胞H/R损伤的影响.RT-PCR和Western印迹结果表明,最适转染浓度50 nmol/L si-PUMA能靶向抑制H/R损伤心肌细胞的PUMA表达;MTT法检测心肌细胞存活率及培养基乳酸脱氢酶（lactate dehydrogenase, LDH）活性测定结果发现,si-PUMA 组细胞存活率较H/R 6 h模型组明显提高,培养液中LDH活性显著降低（P<0.01）;分光光度法及Annexin V-FITC/PI联合染色流式细胞凋亡检测结果显示,si-PUMA组caspase-3活性较H/R 6h组明显下调,细胞凋亡率明显降低（P <0.01）;RT-PCR结果 提示,与H/R 6 h组相比,si-PUMA组Bax及Bcl-2表达分别出现显著下调及上调（P <0.05）.以上结果表明,靶向PUMA的siRNA转染能明显增强心肌细胞耐受H/R损伤的能力,对心肌细胞具有较好的保护作用;PUMA介导H/R诱导的心肌细胞凋亡,是心肌缺血/再灌注损伤基因治疗的一个潜在靶点.     

ASPP2以p53非依赖形式促进自噬引起Hep3B细胞凋亡

p53凋亡刺激蛋白2（apoptosis stimulating protein 2 of p53, ASPP2）能特异性地与p53蛋白结合并增强其促凋亡的功能,进而发挥抗肿瘤作用. 本室前期研究发现,ASPP2可以通过p53-DRAM自噬途径诱导细胞凋亡. 在本研究中,利用ASPP2 腺病毒感染Hep3B细胞(p53缺陷型肝癌细胞系)并用甲基磺酸(MMS)处理后; Calcein AM/PI和M30染色检测细胞凋亡;GFP-LC3质粒转染细胞后检测自噬; 荧光定量PCR和免疫印迹检测自噬基因表达. 结果表明,ASPP2在p53缺陷的Hep3B细胞内可诱导发生凋亡;在MMS存在和缺失条件下, Adr-ASPP2均引起自噬体水平升高及自噬基因的表达增 加,且MMS协同Adr-ASPP2能使自噬水平增加; 进一步用VPS34 siRNA和DRAM siRNA抑 制自噬发现,细胞凋亡水平下降, 说明由Adr-ASPP2诱发经损伤相关自噬调节蛋白（ DRAM）介导的自噬参与了肝癌细胞系凋亡的发生. 综上结果表明,ASPP2可以通过非p53依赖的DRAM介导自噬,并促进肝癌细胞凋亡. 该研究可为肝癌的基因治疗提供新的思路.     

中药干预慢性心力衰竭心肌细胞凋亡的研究进展

心肌细胞凋亡是心力衰竭的重要病理变化,是心衰从代偿走向失代偿的转折点.中药在调控心衰心肌细胞凋亡中发挥着重要作用,已成为现阶段的研究热点.中药主要通过调控相关凋亡因子及信号通路(线粒体信号通路、死亡受体信号通路、内质网信号通路、Hippo通路、Bcl-2家族、caspase家族、p53等),发挥抑制心肌细胞凋亡的作用,...     

A DR4:tBID axis drives the p53 apoptotic response by promoting oligomerization of poised BAX

The cellular response to p53 activation varies greatly in a stimulus- and cell type-specific manner. Dissecting the molecular mechanisms defining these cell fate choices will assist the development of effective p53-based cancer therapies and also illuminate fundamental processes by which gene networks control cellular behaviour. Using an experimental system wherein stimulus-specific p53 responses are elicited by non-genotoxic versus genotoxic agents, we discovered a novel mechanism that determines whether cells undergo proliferation arrest or cell death. Strikingly, we observe that key mediators of cell-cycle arrest (p21, 14-3-3σ) and apoptosis (PUMA, BAX) are equally activated regardless of outcome. In fact, arresting cells display strong translocation of PUMA and BAX to the mitochondria, yet fail to release cytochrome C or activate caspases. Surprisingly, the key differential events in apoptotic cells are p53-dependent activation of the DR4 death receptor pathway, caspase 8-mediated cleavage of BID, and BID-dependent activation of poised BAX at the mitochondria. These results reveal a previously unappreciated role for DR4 and the extrinsic apoptotic pathway in cell fate choice following p53 activation.     

Knockdown of hepatoma-derived growth factor-related protein-3 induces apoptosis of H1299 cells via ROS-dependent and p53-independent NF-κB activation

We previously identified hepatoma-derived growth factor-related protein-3 (HRP-3) as a radioresistant biomarker in p53 wild-type A549 cells and found that p53-dependent induction of the PUMA pathway was a critical event in regulating the radioresistant phenotype. Here, we found that HRP-3 knockdown regulates the radioresistance of p53-null H1299 cells through a distinctly different molecular mechanism. HRP-3 depletion was sufficient to cause apoptosis of H1299 cells by generating substantial levels of reactive oxygen species (ROS) through inhibition of the Nrf2/HO-1 antioxidant pathway. Subsequent, ROS-dependent and p53-independent NF-κB activation stimulated expression of c-Myc and Noxa proteins, thereby inducing the apoptotic machinery. Our results thus extend the range of targets for the development of new drugs to treat both p53 wild-type or p53-null radioresistant lung cancer cells.     

PML-dependent apoptosis after DNA damage is regulated by the checkpoint kinase hCds1/Chk2

The promyelocytic leukaemia (PML) gene is translocated in most acute promyelocytic leukaemias and encodes a tumour suppressor protein. PML is involved in multiple apoptotic pathways and is thought to be pivotal in gamma irradiation-induced apoptosis. The DNA damage checkpoint kinase hCds1/Chk2 is necessary for p53-dependent apoptosis after gamma irradiation. In addition, gamma irradiation-induced apoptosis also occurs through p53-independent mechanisms, although the molecular mechanism remains largely unknown. Here, we report that hCds1/Chk2 mediates gamma irradiation-induced apoptosis in a p53-independent manner through an ataxia telangiectasia-mutated (ATM)-hCds1/Chk2-PML pathway. Our results provide the first evidence of a functional relationship between PML and a checkpoint kinase in gamma irradiation-induced apoptosis.     

Anti-cancer effects of JKA97 are associated with its induction of cell apoptosis via a Bax-dependent and p53-independent pathway

p53, one of the most commonly mutated genes in human cancers, is thought to be associated with cancer development. Hence, screening and identifying natural or synthetic compounds with anti-cancer activity via p53-independent pathway is one of the most challenging tasks for scientists in this field. Compound JKA97 (methoxy-1-styryl-9H-pyrid-[3,4-b]-indole) is a small molecule synthetic anti-cancer agent, with unknown mechanism(s). In this study we have demonstrated that the anti-cancer activity of JKA97 is associated with apoptotic induction via p53-independent mechanisms. We found that co-incubation of human colon cancer HCT116 cells with JKA97 inhibited HCT116 cell anchorage-independent growth in vitro and tumorigenicity in nude mice and also induced a cell apoptotic response, both in the cell culture model and in a tumorigenesis nude mouse model. Further studies showed that JKA97-induced apoptosis was dramatically impaired in Bax knock-out (Bax(-/-)) HCT116 cells, whereas the knock-out of p53 or PUMA did not show any inhibitory effects. The p53-independent apoptotic induction by JKA97 was confirmed in other colon cancer and hepatocarcinoma cell lines. In addition, our results showed an induction of Bax translocation and cytochrome c release from the mitochondria to the cytosol in HCT116 cells, demonstrating that the compound induces apoptosis through a Bax-initiated mitochondria-dependent pathway. These studies provide a molecular basis for the therapeutic application of JKA97 against human cancers with p53 mutations.